Search research articles
Contact Us
Filters
Showing results (321-330 of 367) with videos related to
Page
of 37
Sort By:
AIDS (London, England)
|
March 20, 2023
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
Marissa Wilck, Shaun Barnabas, Kulkanya Chokephaibulkit, et al.
Journal of Clinical Microbiology
|
June 1, 2007
Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA
Maria da Gloria S Carvalho, Maria Lucia Tondella, Karen McCaustland, et al.
Computer Methods and Programs in Biomedicine
|
September 13, 2023
Testing the performance, adequacy, and applicability of an artificial intelligence model for pediatric pneumonia diagnosis
Sara Domínguez-Rodríguez, Helena Liz-López, Angel Panizo-LLedot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 10, 2024
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)
Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, et al.
Vaccine
|
December 15, 2022
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)
Androniki Bili, Scott Dobson, Jeffrey Quinones, et al.
Blood Advances
|
November 16, 2022
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Charles T Quinn, Richard T Wiedmann, Daniel Jarovsky, et al.
Vaccine
|
January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Open Forum Infectious Diseases
|
February 11, 2022
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
Laura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
AIDS (London, England)
|
November 9, 2021
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, et al.
Vaccine
|
September 7, 2021
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
Joon-Young Song, Chih-Jen Chang, Charles Andrews, et al.
Page
of 37
Search research articles
Search
Showing results (321-330 of 367) with videos related to
Sort By:
Page
of 37
AIDS (London, England)
|
March 20, 2023
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
Marissa Wilck, Shaun Barnabas, Kulkanya Chokephaibulkit, et al.
Journal of Clinical Microbiology
|
June 1, 2007
Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA
Maria da Gloria S Carvalho, Maria Lucia Tondella, Karen McCaustland, et al.
Computer Methods and Programs in Biomedicine
|
September 13, 2023
Testing the performance, adequacy, and applicability of an artificial intelligence model for pediatric pneumonia diagnosis
Sara Domínguez-Rodríguez, Helena Liz-López, Angel Panizo-LLedot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 10, 2024
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)
Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, et al.
Vaccine
|
December 15, 2022
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)
Androniki Bili, Scott Dobson, Jeffrey Quinones, et al.
Blood Advances
|
November 16, 2022
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Charles T Quinn, Richard T Wiedmann, Daniel Jarovsky, et al.
Vaccine
|
January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Open Forum Infectious Diseases
|
February 11, 2022
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
Laura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
AIDS (London, England)
|
November 9, 2021
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, et al.
Vaccine
|
September 7, 2021
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
Joon-Young Song, Chih-Jen Chang, Charles Andrews, et al.
Page
of 37